Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE‐TIMI 58 trial: A nationwide observational study

AIMS: To investigate cardiovascular (CV) safety and event rates for dapagliflozin versus other glucose‐lowering drugs (GLDs) in a real‐world type 2 diabetes population after applying the main inclusion criteria and outcomes from the DECLARE‐TIMI 58 study. METHODS: Patients with new initiation of dap...

Descripción completa

Detalles Bibliográficos
Autores principales: Norhammar, Anna, Bodegård, Johan, Nyström, Thomas, Thuresson, Marcus, Nathanson, David, Eriksson, Jan W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593417/
https://www.ncbi.nlm.nih.gov/pubmed/30609272
http://dx.doi.org/10.1111/dom.13627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593417/
https://www.ncbi.nlm.nih.gov/pubmed/30609272
http://dx.doi.org/10.1111/dom.13627

Ejemplares similares